A new technique to reduce epistaxis and enhance navigability during nasotracheal intubation.

BACKGROUND: Epistaxis is the most common complication of nasotracheal intubation. We compared endotracheal tubes (ETT) obturated with an inflated esophageal stethoscope with normal ETTs with regard to the prevention of epistaxis and navigability, both with and without thermosoftening. METHODS: Dental surgical patients requiring nasotracheal intubation were randomly allocated into 1 of 4 groups (n = 50 each): Group 1, nonthermosoftened ETTs; Group 2, nonthermosoftened ETTs obturated with an inflated esophageal stethoscope; Group 3, thermosoftened ETTs; and Group 4, thermosoftened ETTs obturated with an inflated esophageal stethoscope. Navigability of ETTs through the nasal cavity and postintubation epistaxis were evaluated. RESULTS: Navigability of ETTs through the nasal cavity was the worst in Group 1 (P = 0.001). Epistaxis was the most severe in Group 1, similar between Groups 2 and 3, and the least severe in Group 4 (P < 0.001). CONCLUSION: The use of esophageal stethoscope-obturated ETTs was effective, and comparable to thermosoftening, in preventing epistaxis associated with nasotracheal intubation. Thermosoftened, obturated ETTs were more effective than simple thermosoftened ETTs in reducing epistaxis.

Stellate ganglion block increases blood flow into the optic nerve head and the peripapillary retina in human.

The effects of stellate ganglion block (SGB) on the blood flow of the optic nerve head (ONH) and the peripapillary retina, which plays an important role in the pathogenesis of a major blinding disease, e.g. glaucoma, are unclear. The aim of this study was to evaluate the effects of a sympathetic block on the blood flow of the ONH and the peripapillary retina. Heidelberg Retinal Flowmetry, which is a system incorporating a noninvasive confocal scanning laser Doppler flow meter, was used to measure the retinal blood flow. A unilateral stellate ganglion block was performed in 11 healthy subjects. The retinal blood flows were measured before, 30 and 120 min after SGB. On each occasion, three scans were obtained and the blood flow was analyzed. The systemic blood pressure (BP) and the intraocular pressure (IOP) were also measured at the set time points. The blood flow of the ONH and the peripapillary retina of the ipsilateral retina was significantly increased (P=0.001) by 106.8% and 98.7%, respectively, 30 min after SGB without accompanying significant changes in BP and IOP when compared to their baseline values; while those of the contralateral eyes did not change. The effect of SGB on blood flow in these areas disappeared 120 min after SGB. In conclusion, SGB may have a beneficial effect on ocular diseases associated with ischemia of the ONH and the peripapillary retina, e.g. glaucoma.

Effects of botulinum toxin type A on bilateral masseteric hypertrophy evaluated with computed tomographic measurement.

BACKGROUND: A paucity of reports exist on the use of botulinum toxin type A injections as an alternative noninvasive treatment for masseteric hypertrophy. OBJECTIVE: To evaluate the effects of botulinum toxin type A on masseteric hypertrophy using computed tomography. METHODS: Percutaneous intramuscular injections of botulinum toxin type A of 30 U per side was carried out in 11 subjects with masseteric hypertrophy. The changes in the masseteric muscle volume before and 12 weeks after injection were evaluated using computed tomography. The changes in the lower facial contours on the photographs were evaluated as excellent, good, fair, and no changes. RESULTS: Nine of the 11 subjects showed a mean reduction of approximately 22% in the masseteric muscle volume. The maximum reduction was 35.4% (range, 8.1% to 35.4%). Nine subjects showed aesthetically good results with a grade of good or excellent at 12 weeks after treatment. CONCLUSION: Botulinum toxin injections are a noninvasive alternative method for treating masseteric hypertrophy.

Effects of botulinum toxin type A on the superior cervical ganglia in rabbits.

Sympathetic neurolysis is very important in treating chronic pain, especially sympathetically maintained pain. However, conventional neurolytic agents destroy nerve fibers nonselectively and may leave serious complications. Botulinum toxin type A (BTA) selectively acts on cholinergic nerves and inhibits the secretion of acetylcholines (Ach) at the involved nerve endings. Because cholinergic nerves also exist in autonomic ganglia, it is believed that BTA has pharmacological effects on sympathetic ganglia. In this study, after the administration of BTA into the superior cervical ganglion (SCG) in rabbits, the possible clinical use of BTA as a neurolytic agent was evaluated. In the normal saline-treated control group, miosis was not observed in all 12 rabbits. However, in the BTA-treated group, 15 cases of miosis were observed among 40 rabbits (37.5%). Furthermore, BTA induced miosis in a dose-dependent manner, though onset time and duration of miosis varied. Mean time of onset and duration were 1.8 days and 5.3 weeks, respectively. By eosin-hematoxylin (H&E) staining finding, no significant chronological and histological changes between the control and the experimental groups were observed. In conclusion, BTA was found to have a sympathetic ganglion blocking effect over a period of more than 1 month without causing considerable pathologic changes in the SCG, that is, this toxin may be used in the case of sympathetically maintained pain control as a sympatholytic.